B-CELL-TARGETED THERAPIES IN THE TREATMENT OF AUTOIMMUNE SKIN DISEASES – A COMPREHENSIVE REVIEW OF MECHANISMS, EFFICACY, AND FUTURE DIRECTIONS
DOI:
https://doi.org/10.31435/ijitss.3(51).2026.5683Keywords:
Autoimmunity, Cellular Immunotherapy, Chimeric Antigen Receptor T Cells, Autoimmune Skin Diseases (AISDs), B Lymphocytes, Anti-CD20 Antibodies, Pemphigus, Pemphigoid, Cutaneous Lupus Erythematosus, SclerodermaAbstract
Autoimmune skin diseases (AISDs) constitute a complex group of conditions whose pathogenesis is based on abnormal activation of the immune system, leading to the production of autoantibodies and damage to skin structures. In recent years, a key role in these processes has been attributed to B lymphocytes, which not only produce autoantibodies but also perform regulatory and effector functions in the immune response. The development of biological therapies targeting B lymphocytes has revolutionized the treatment of many diseases, particularly pemphigus, where anti-CD20 antibodies have become the standard of care.
The aim of this article is to provide a comprehensive overview of the role of B lymphocytes in the pathogenesis of AISD, an overview of available targeted therapies (including monoclonal antibodies, kinase inhibitors, and plasma cell-targeted therapies), and an analysis of their efficacy, safety, and limitations. Attention was paid to new therapeutic strategies that may enable more selective and sustained modulation of the immune response.
References
Yurasov, S., Wardemann, H., Hammersen, J., et al. (2005). Defective B cell tolerance checkpoints in systemic lupus erythematosus. J Exp Med, 201(5), 703–711. PMID: 15738055.
Meffre, E., & O’Connor, K. C. (2019). Impaired B-cell tolerance checkpoints promote the development of autoimmune diseases and pathogenic autoantibodies. Immunol Rev, 292(1), 90–101. PMID: 31746097.
Amber, K. T., Valdebran, M., & Grando, S. A. (2018). Non-desmoglein antibodies in patients with pemphigus vulgaris. Front Immunol, 9, 1190. PMID: 29997613.
Mesin, L., Ersching, J., & Victora, G. D. (2016). Germinal center B cel dynamics. Immunity, 45(3), 471–482. PMID: 27653600.
Hammers, C. M., & Stanley, J. R. (2016). Mechanisms of disease: pemphigus and bullous pemphigoid. Annu Rev Pathol, 11, 175–197. PMID: 26907530.
Wang, L., Wang, F. S., & Gershwin, M. E. (2015). Human autoimmune diseases: a comprehensive update. J Intern Med, 278(4), 369–395. PMID: 26060079.
Mauri, C., & Bosma, A. (2012). Immune regulatory function of B cells. Annu Rev Immunol, 30, 221–241. PMID: 22224776.
Tangye, S. G., & Tarlinton, D. M. (2009). Memory B cells: effectors of long-lived immune responses. Eur J Immunol, 39(8), 2065–2075. PMID: 19637202.
Schmidt, E., & Zillikens, D. (2013). Pemphigoid diseases. Lancet, 381(9863), 320–332. PMID: 23237401.
Hofmann, S. C., Juratli, H. A., Bruckner-Tuderman, L., et al. (2018). Long-lived plasma cells and autoimmune diseases. Autoimmun Rev, 17(5), 457–463. PMID: 29501751.
Odegard, J. M., Marks, B. R., DiPlacido, L. D., et al. (2008). ICOS-dependent extrafollicular helper T cells elicit IgG production via IL-21 in systemic autoimmunity. J Exp Med, 205(12), 2873–2886. PMID: 18981238.
Vinuesa, C. G., Sanz, I., & Cook, M. C. (2009). Dysregulation of germinal centres in autoimmune disease. Nat Rev Immunol, 9(12), 845–857. PMID: 19935804.
Bradley, J. R. (2008). TNF-mediated inflammatory disease. J Pathol, 214(2), 149–160. PMID: 18161752.
Kowalewski, C., Dmochowski, M., Placek, W., et al. (2014). Diagnostyka i leczenie pęcherzycy – konsensus Polskiego Towarzystwa Dermatologicznego. Przegl Dermatol, 101(2), 147–155.
Kneisel, A., & Hertl, M. (2011). Autoimmune bullous skin diseases. Part 1: clinical manifestations. J Dtsch Dermatol Ges, 9(10), 844–856. https://doi.org/10.1111/j.1610-0387.2011.07793.x
Hertl, M., Kárpáti, S., Borradori, L., Feliciani, C., Joly, P., Kowalewski, C., et al. (2015). Pemphigus. S2 Guideline for diagnosis and treatment guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatol Venereol, 29(3), 405–414. https://doi.org/10.1111/jdv.12772
Amber, K. T., Murrell, D. F., Schmidt, E., et al. (2018). Autoimmune subepidermal blistering diseases of the skin and mucosae. Clin Rev Allergy Immunol, 54(1), 26–51. PMID: 27896658.
Di Zenzo, G., Della Torre, R., Zambruno, G., & Borradori, L. (2012). Bullous pemphigoid: from the clinic to the bench. Clin Dermatol, 30(1), 3–16. PMID: 22137224.
Kridin, K., & Ludwig, R. J. (2018). The growing incidence of bullous pemphigoid: overview and potential explanations. Front Med (Lausanne), 5, 220. PMID: 30155302.
Tsokos, G. C. (2011). Systemic lupus erythematosus. N Engl J Med, 365(22), 2110–2121. PMID: 22129255.
Lisnevskaia, L., Murphy, G., & Isenberg, D. (2014). Systemic lupus erythematosus. Lancet, 384(9957), 1878–1888. PMID: 24881804.
Crow, M. K. (2014). Type I interferon in the pathogenesis of lupus. J Immunol, 192(12), 5459–5468. PMID: 24907379.
Kuhn, A., Landmann, A., & Bonsmann, G. (2014). Flares in cutaneous lupus erythematosus. Autoimmun Rev, 13(3), 291–298. PMID: 24189258.
Stohl, W. (2006). Systemic lupus erythematosus and BAFF. Curr Dir Autoimmun, 8, 120–138. PMID: 16490911.
Joly, P., Maho-Vaillant, M., Prost-Squarcioni, C., et al. (2017). First-line rituximab combined with short-term prednisone versus prednisone alone for pemphigus. Lancet, 389(10083), 2031–2040. PMID: 28342637.
Amber, K. T., & Hertl, M. (2018). An assessment of treatment responses in pemphigus vulgaris. Front Immunol, 9, 1675. PMID: 30013585.
Maloney, D. G., Smith, B., & Rose, A. (2002). Rituximab: mechanism of action and resistance. Semin Oncol, 29(1 Suppl 2), 2–9. PMID: 11842388.
Weiner, G. J. (2010). Rituximab: mechanism of action. Semin Hematol, 47(2), 115–123. PMID: 20350658.
Taylor, R. P., & Lindorfer, M. A. (2008). Analyses of CD20 monoclonal antibody-mediated tumor cell killing mechanisms. Immunol Rev, 221, 204–216. PMID: 18275484.
Golay, J., & Introna, M. (2012). Mechanism of action of therapeutic monoclonal antibodies: promises and pitfalls of in vitro and in vivo assays. Arch Biochem Biophys, 526(2), 146–153. PMID: 22405918.
Cragg, M. S., Walshe, C. A., Ivanov, A. O., & Glennie, M. J. (2005). The biology of CD20 and its potential as a target for mAb therapy. Curr Dir Autoimmun, 8, 140–174. PMID: 15564719.
Ahmed, A. R., Spigelman, Z., Cavacini, L. A., & Posner, M. R. (2006). Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med, 355(17), 1772–1779. PMID: 17065639.
DiLillo, D. J., Hamaguchi, Y., Ueda, Y., et al. (2008). Maintenance of long-lived plasma cells and serological memory despite mature and memory B cell depletion during CD20 immunotherapy in mice. J Immunol, 180(1), 361–371. PMID: 18097037.
Colliou, N., Picard, D., Caillot, F., et al. (2013). Long-term remissions of pemphigus after rituximab therapy are associated with prolonged failure of desmoglein B cell response. Sci Transl Med, 5(175), 175ra30. PMID: 23486778.
Lund, F. E. (2008). Cytokine-producing B lymphocytes-key regulators of immunity. Curr Opin Immunol, 20(3), 332–338. PMID: 18417336.
Stasi, R., Del Poeta, G., Stipa, E., et al. (2007). Response to B-cell-depleting therapy with rituximab reverts the abnormalities of T-cell subsets in patients with idiopathic thrombocytopenic purpura. Blood, 110(8), 2924–2930. PMID: 17638856.
Cancro, M. P., D’Cruz, D. P., & Khamashta M.A (2009). The role of B lymphocyte stimulator (BLyS) in systemic lupus erythematosus. J. Clin. Invest., 119, 1066–1073.
Dorota Suszek, Radosław Jeleniewicz, Maria Majdan Terapie biologiczne w toczniu rumieniowatym układowym,. https://doi.org/10.5604/17322693.1007663
Gottenberg, J. E., Guillevin, L., Lambotte, O., Combe, B., Allanore, Y., Cantagrel, A., Larroche, C., Soubrier, M., Bouillet, L., Dougados, M., Fain, O., Farge, D., Kyndt, X., Lortholary, O., Masson, C., Moura, B., Remy, P., Thomas, T., Wendling, D., Anaya, J. M., Sibilia, J., & Mariette X.; Club Rheumatismes et Inflammation (CRI) (2005). Tolerance and short term efficacy of rituximab in 43 patients wits systemic autoimmune diseases. Ann. Rheum. Dis., 64, 913–920.
F.J. Navarro-Triviñoa, R. Ruiz-Villaverdeb, Bruton's Tyrosine Kinase (BTK) Inhibitors: A New Therapeutic Frontier in Dermatology,. https://doi.org/10.1016/j.ad.2026.104606
M. Metz, A. Giménez-Arnau, M. Hide i in. Remibrutinib w przewlekłej pokrzywce spontanicznej., N Engl J Med, 392 (2025), s. 984-994.
Radbruch, A., Muehlinghaus, G., Luger, E. O., et al. (2006). Competence and competition: the challenge of becoming a long-lived plasma cell. Nat Rev Immunol, 6(10), 741–750. PMID: 16977339.
Neubert, K., Meister, S., Moser, K., et al. (2008). The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med, 14(7), 748–755. PMID: 18587408.
Alexander, T., Sarfert, R., Klotsche, J., et al. (2015). The proteasome inhibitior bortezomib depletes autoreactive plasma cells and ameliorates clinical disease in refractory systemic lupus erythematosus. Ann Rheum Dis, 74(7), 1474–1478. PMID: 25712815.
Moreau, P., Richardson, P. G., Cavo, M., et al. (2012). Proteasome inhibitors in multiple myeloma: 10 years later. Blood, 120(5), 947–959. PMID: 22611150.
van de Donk, N. W. C. J., Janmaat, M. L., Mutis, T., et al. (2016). Monoclonal antibodies targeting CD38 in hematological malignancies and beyond. Immunol Rev, 270(1), 95–112. PMID: 26864113.
Scheibe, F., Ostendorf, L., Prüss, H., et al. (2022). Daratumumab for treatment-refractory antibody-mediated diseases in neurology. Eur J Neurol, 29(6), 1847–1854. PMID: 35187866.
Berry, C. T., Frazee, C. S., Herman, P. J., et al. (2025). Current advances in cellular immunotherapy for autoimmune diseases. Semin Immunopathol, 47, 7. https://doi.org/10.1007/s00281-024-01034-5
Mougiakakos, D., Krönke, G., Völkl, S., Kretschmann, S., Aigner, M., Kharboutli, S., Böltz, S., Manger, B., Mackensen, A., & Schett, G. (2021). CD19-Targeted CAR T cells in refractory systemic Lupus Erythematosus. N Engl J Med, 385(6), 567–569.
Denton, C. P., & Khanna, D. (2017). Systemic sclerosis. Lancet, 390(10103), 1685–1699.
Hu, S., Hou, Y., Wang, Q., Li, M., Xu, D., & Zeng, X. (2018). Prognostic profile of systemic sclerosis: analysis of the clinical EUSTAR cohort in China. Arthritis Res Ther, 20(1), 235.
Merkt, W., Freitag, M., Claus, M., Kolb, P., Falcone, V., Röhrich, M., Rodon, L., Deicher, F., Andreeva, I., Tretter, T., Tykocinski, L. O., Blank, N., Watzl, C., Schmitt, A., Sauer, T., Müller-Tidow, C., Polke, M., Heußel, C. P., Dreger, P., Lorenz, H. M., & Schmitt, M. (2024). Third-generation CD19.CAR-T cell-containing combination therapy in Scl70 + systemic sclerosis. Ann Rheum Dis, 83(4), 543–546.
Ellebrecht, C. T., Bhoj, V. G., Nace, A., Choi, E. J., Mao, X., Cho, M. J., Di Zenzo, G., Lanzavecchia, A., Seykora, J. T., Cotsarelis, G., Milone, M. C., & Payne, A. S. (2016). Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease. Science, 353(6295), 179–184.
F.J. Navarro-Triviñoa, R. Ruiz-Villaverdeb, Bruton's Tyrosine Kinase (BTK) Inhibitors: A New Therapeutic Frontier in Dermatology,. https://doi.org/10.1016/j.ad.2026.104606
Khalaf Kridin, Emerging treatment options for the management of pemphigus vulgaris,. https://doi.org/10.2147/TCRM.S142471
Russo I., Ultra-low dose rituximab for refractory pemghigus vulgaris: a pilot study,. https://doi.org/10.1080/14712598.2020.1727440
Ciolfi, C. (2022). Role of Rituximab in the Treatment of Pemphigus Vulgaris: Patient Selection and Acceptability. Patient Prefer Adherence, 16, 3035–3043. https://doi.org/10.2147/PPA.S350756
Tai YT, Anderson KC. , Targeting B-cell maturation antigen in multiple myeloma, Immunotherapy. 2015;7(11):1187–1199.
Palanichamy, A., Barnard, J., Zheng, B., et al. (2009). Novel human transitional B cell populations revealed by B cell depletion therapy. J Immunol, 182(10), 5982–5993. PMID: 19414749.
Anolik, J. H., Friedberg, J. W., Zheng, B., et al. (2007). B cell reconstitution after rituximab treatment of lymphoma recapitulates B cell ontogeny. Clin Immunol, 122(2), 139–145. PMID: 17185084.
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Patryk Brzezicki, Natalia Bębenek, Gabriela Barszcz, Monika Błądek, Karolina Drygała, Sylwia Wit, Paulina Frączkiewicz , Izabela Harpula , Radosław Ramotowski , Justyna Bogdan, Benedykt Baljon
This work is licensed under a Creative Commons Attribution 4.0 International License.
All articles are published in open-access and licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0). Hence, authors retain copyright to the content of the articles.
CC BY 4.0 License allows content to be copied, adapted, displayed, distributed, re-published or otherwise re-used for any purpose including for adaptation and commercial use provided the content is attributed.
